Zenas BioPharma Q3 2026 net loss more than doubles year over year to $108.9 million

Bitget2026/11/05 12:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zenas BioPharma’s third-quarter 2026 net loss more than doubled year over year to $108.9 million.
Revenue rose to $10 million from no revenue a year earlier, attributable to a Bristol Myers Squibb development milestone.
Research and development expenses climbed 70% year over year to $58.5 million, primarily due to higher clinical, regulatory and personnel costs.
Cash, cash equivalents and investments totaled $647.1 million at September 30, 2026.
The FDA’s target action date for obexelimab in IgG4-related disease is May 27, 2027; the European marketing application was validated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870813) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zenas BioPharma Q3 2026 net loss more than doubles year over year to $108.9 million

You may also like

Crypto prices